Ul­tragenyx to seek ac­cel­er­at­ed ap­proval for rare dis­ease gene ther­a­py

Ul­tragenyx moved one step clos­er to es­tab­lish­ing a new sur­ro­gate bio­mark­er for ac­cel­er­at­ed ap­proval in rare dis­ease gene ther­a­pies.

The biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.